http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-106612-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a045f1ebc0077bddc1b1d8200a579376 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate | 2016-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-106612-A1 |
| titleOfInvention | SALTS, CRYSTAL SHAPES AND PHARMACEUTICAL COMPOSITIONS OF 4- [2- (4-AMINO-PIPERIDIN-1-IL) -5- (3-FLUORO-4-METOXI-PHENIL) -1-METIL-6-OXO-1,6 -DIHIDRO-PIRIMIDIN-4-IL] -2-FLUOROBENZONITRILE AS A SPECIFIC DEMETILASE INHIBITOR OF LISINA |
| abstract | Amorphous and crystalline forms of pharmaceutically acceptable salts of lysine specific demethylase 1 inhibitor 4- [2- (4-amino-piperidin-1-yl) -5- (3-fluoro-4-methoxy-phenyl) are described ) -1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl] -2-fluorobenzonitrile. Pharmaceutical compositions suitable for administration to a mammal are also described, including the lysine specific demethylase 1 inhibitor, and methods of using lysine specific methylase 1 inhibitor to treat diseases or conditions associated with the specific demethylase 1 activity of lysine Claim 1: A pharmaceutically acceptable salt of 4- [2- (4-amino-piperidin-1-yl) -5- (3-fluoro-4-methoxy-phenyl) -1-methyl-6-oxo-1,6 -dihydro-pyrimidin-4-yl] -2-fluorobenzonitrile, wherein the pharmaceutically acceptable salt is in crystalline form. Claim 4: A crystalline Form 1 of 4- [2- (4-amino-piperidin-1-yl) -5- (3-fluoro-4-methoxy-phenyl) -1-methyl-6-oxo-1,6 -dihydro-pyrimidin-4-yl] -2-fluorobenzonitrile besylate salt, characterized by having: (a) a powder X-ray diffraction pattern (XRPD) substantially equal to that shown in Figure 7; (b) a powder X-ray diffraction pattern (XRPD) with characteristic peaks at 4.9º 2-q, 9.7º 2-q, 13.4º 2-q, 18.0º 2-q, 18.5º 2-q, 1; (c) a DSC thermogram with an endotherm having a starting temperature of approximately 317 ° C; (d) a DSC thermogram substantially similar to that shown in Figure 6; or (e) combinations of them. Claim 14: 4- [2- (4-amino-piperidin-1-yl) -5- (3-fluoro-4-methoxy-phenyl) -1-methyl-6-oxo-1,6-dihydro-pyrimidin- 4-yl] -2-fluorobenzonitrile besylate salt, which is in amorphous form. |
| priorityDate | 2015-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.